GlaxoSmithKline's GSK cervical cancer vaccine, Cervarix, may have the edge over US rival Merck's product Gardasil, according to trial results presented this week in America. GlaxoSmithKline's GSK cervical cancer vaccine, Cervarix, may have the edge over US rival Merck's product Gardasil, according...
GlaxoSmithKline GSK, which announces its first-quarter results on 28 April, has had something of a mixed start to the year. While the drug giant's new cervical cancer vaccine, Cervarix, has been hailed as a potential blockbuster by analysts, manufa GlaxoSmithKline GSK, which announces its first-quarter results...
GlaxoSmithKline has taken the brave step of pitting its new cervical cancer vaccine, Cervarix, head-to-head against rival Merck's product, Gardasil. Over a period of 12 months, the Phase III trial will compare the immune responses of female patients GlaxoSmithKline has taken the brave step of...
POWER PLAY: David Stout has GSK in a good spot. Glaxo has a strong franchise in its diabetes medications and asthma inhaler Advair. Its pipeline is considered good. It has sought FDA approval for cervical cancer vaccine Cervarix, as well as migraine POWER PLAY: David...
Alongside its peers, AstraZeneca and Shire, GlaxoSmithKline GSK posted a robust set of first-quarter figures, which pushed its shares up 4 per cent to 1,548p. During the period, the pharma giant filed its cervical cancer vaccine, Cervarix, for appr Alongside its peers, AstraZeneca and Shire, GlaxoSmithKline...